SynthesisBreast cancer research and treatment2026
Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis.
Caio Dabbous de Liz et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.